0000000000339560

AUTHOR

Alessandro Sanduzzi

showing 8 related works from this author

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic…

2015

Inhaled corticosteroids (ICS) are frequently recommended for the treatment of asthma and COPD, often in combination with long-acting beta2-agonists (LABA), depending on the severity of the disease and/or on the specific phenotype. Several ICS/LABA combinations are currently available that differ in their pharmacokinetic characteristics and dose of both components. Thus, this review assesses differences in the efficacy and the safety profiles of the ICS components in the two more frequently used ICS/LABA combinations (budesonide/formoterol and fluticasone/salmeterol) for the management of COPD. Whereas the basic mechanism of action is similar for all ICS (binding with the intracellular gluco…

BudesonideAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classPopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioBudesonide; COPD; Fluticasone; Pneumonia; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Drug Combinations; Glucocorticoids; Humans; Pulmonary Disease Chronic Obstructive; Quality of Life; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)Pulmonary DiseasePulmonary Disease Chronic ObstructiveGlucocorticoidInternal medicineDrug CombinationAdministration InhalationmedicineBudesonide; COPD; Fluticasone; Pneumonia; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical)HumansCOPDPharmacology (medical)educationBudesonideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAsthmaFluticasoneeducation.field_of_studyCOPDbusiness.industryBiochemistry (medical)Pneumoniamedicine.diseaserespiratory tract diseasesDrug CombinationsInhalationAnesthesiaAdministrationQuality of LifeCorticosteroidFluticasoneFormoterolSalmeterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugHuman
researchProduct

Analysis of Mycobacterium tuberculosis-Specific CD8 T-Cells in Patients with Active Tuberculosis and in Individuals with Latent Infection

2009

CD8 T-cells contribute to control of Mycobacterium tuberculosis infection, but little is known about the quality of the CD8 T-cell response in subjects with latent infection and in patients with active tuberculosis disease. CD8 T-cells recognizing epitopes from 6 different proteins of Mycobacterium tuberculosis were detected by tetramer staining. Intracellular cytokines staining for specific production of IFN-gamma and IL-2 was performed, complemented by phenotyping of memory markers on antigen-specific CD8 T-cells. The ex-vivo frequencies of tetramer-specific CD8 T-cells in tuberculous patients before therapy were lower than in subjects with latent infection, but increased at four months a…

MaleEpitopes T-Lymphocytelcsh:MedicineCD8-Positive T-LymphocytesEpitopeDiagnostic RadiologyInfectious Diseases/Bacterial InfectionsSpectrum Analysis TechniquesCellular typesCytotoxic T celllcsh:ScienceImage Cytometryeducation.field_of_studyMultidisciplinarybiologyRadiology and ImagingImmune cellsInfection ImagingMiddle AgedFlow CytometryActinobacteriaPhenotypeSpectrophotometryCytokinesWhite blood cellsFemaleCytophotometryResearch Articlemedicine.drugInterleukin 2Cell biologyBlood cellsTuberculosisImaging TechniquesImmunologyPopulationT cellsCytotoxic T cellsResearch and Analysis MethodsMycobacterium tuberculosisDiagnostic MedicineImmunology/Immunity to InfectionsHLA-A2 AntigenmedicineHumansTuberculosiseducationMedicine and health sciencesHLA-A AntigensBacteriaFluorimetrylcsh:ROrganismsBiology and Life SciencesMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseVirologyRetractionAnimal cellsImmunology/Immune ResponseImmunologyMycobacterium tuberculosis CD8 T cells Tuberculosis Latent Infectionlcsh:QCD8MycobacteriumPLoS ONE
researchProduct

Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection.

2010

Th1 CD4(+) T cells and their derived cytokines are crucial for protection against Mycobacterium tuberculosis. Using multiparametic flow cytometry, we have evaluated the distribution of seven distinct functional states (IFN-gamma/IL-2/TNF-alpha triple expressors, IFN-gamma/IL-2, IFN-gamma/TNF-alpha or TNF-alpha/IL-2 double expressors or IFN-gamma, IL-2 or TNF-alpha single expressors) of CD4(+) T cells in individuals with latent M. tuberculosis infection (LTBI) and active tuberculosis (TB). We found that triple expressors, while detectable in 85-90%TB patients, were only present in 10-15% of LTBI subjects. On the contrary, LTBI subjects had significantly higher (12- to 15-fold) proportions of…

Interleukin 2AdultCD4-Positive T-LymphocytesMaleTuberculosisSettore MED/17 - Malattie InfettiveImmunologyCell SeparationBiologyLymphocyte ActivationFlow cytometryMycobacterium tuberculosis03 medical and health sciences0302 clinical medicineImmune systemBacterial ProteinsCD4(+) T cells Cytokines Mycobacterium tuberculosis infection Tuberculosis disease interferon-gamma immunological memory disease responses protection cytokine immunity bcg vaccination virusmedicineImmunology and AllergyDistribution (pharmacology)HumansCytokineTuberculosis Pulmonary030304 developmental biologyTuberculosis disease.Settore MED/04 - Patologia Generale0303 health sciencesAntigens Bacterialmedicine.diagnostic_testMycobacterium tuberculosis infectionMycobacterium tuberculosisMiddle Agedbiology.organism_classificationmedicine.diseaseFlow CytometryPhenotypeVirologyCD4+ T cellsBacterial Load3. Good healthImmunologyAcute DiseaseChronic DiseaseCytokinesTumor necrosis factor alphaAcyltransferases030215 immunologymedicine.drugEuropean journal of immunology
researchProduct

Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?

2015

Inhalation is the preferred route of drug administration in chronic respiratory diseases because it optimises delivery of the active compounds to the targeted site and minimises side effects from systemic distribution. The choice of a device should be made after careful evaluation of the patient's clinical condition (degree of airway obstruction, comorbidities), as well as their ability to coordinate the inhalation manoeuvre and to generate sufficient inspiratory flow. These patient factors must be aligned with the specific advantages and limitations of each inhaler when making this important choice. Finally, adherence to treatment is not the responsibility of the patient alone, but should …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveSocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Anti-asthmatic AgentMedication AdherencePulmonary DiseasePulmonary Disease Chronic ObstructiveSuspensionsAdministration InhalationmedicineCOPDHumansPharmacology (medical)Anti-Asthmatic AgentsMetered Dose InhalersRespiratory systemParticle SizeIntensive care medicineAsthmaAdherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical); Medicine (all)COPDInhalationbusiness.industryMedicine (all)InhalerNebulizers and VaporizersBiochemistry (medical)Adherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)InhalerDry Powder InhalersAirway obstructionmedicine.diseaseAsthmaSolutionsInhalationAdherenceAdministrationAdherence; Asthma; COPD; InhalerbusinessPulmonary pharmacologytherapeutics
researchProduct

Corrigendum to “Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?” [YPUPT 31C (2015) 63–67]

2015

NA

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryInhalerBiochemistry (medical)MedicinePharmacology (medical)asthmaSettore MED/10 - Malattie Dell'Apparato RespiratorioRespiratory systembusinessIntensive care medicineAffect (psychology)Pulmonary Pharmacology & Therapeutics
researchProduct

Quality standards for the management of bronchiectasis in Italy: A national audit

2016

Although historically considered a neglected disease, bronchiectasis has become a disease of renewed interest over recent decades in light of an increase in prevalence and a substantial burden on healthcare systems. In 2010, the British Thoracic Society (BTS) published guidelines on the management of bronchiectasis in adults, along with specific quality standards. To date, these represent the only quality standards available in Europe. These have been tested over a number of years in the UK with progressive improvements in the standard of care. No national guidelines are available in Italy and no indications on which guideline should be followed have been given by the Italian Society of Res…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtybronchiectasismedia_common.quotation_subjectSymptom Flare UpMedical auditSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciences0302 clinical medicinemedicinePrevalenceHumansQuality (business)Pseudomonas Infections030212 general & internal medicineIntensive care medicineNational auditmedia_commonAgedMedical AuditBronchiectasisbusiness.industryMedicine (all)Middle Agedmedicine.diseaseSymptom Flare UpAnti-Bacterial AgentsPatient Care Management030228 respiratory systemItalyNeeds assessmentPseudomonas aeruginosaFemalebusinessMedicine (all); Pulmonary and Respiratory MedicineNeeds Assessment
researchProduct

Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view.

2014

Randomized Controlled Trials (RCTs) are the "gold standard" for evaluating treatment outcomes providing information on treatments "efficacy". They are designed to test a therapeutic hypothesis under optimal setting in the absence of confounding factors. For this reason they have high internal validity. The strict and controlled conditions in which they are conducted, leads to low generalizability because they are performed in conditions very different from real life usual care. Conversely, real life studies inform on the "effectiveness" of a treatment, that is, the measure of the extent to which an intervention does what is intended to do in routine circumstances. At variance to RCTs, real …

Pulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtyAsthma; COPD; Randomized controlled trials; Real life studies; Asthma; Confounding Factors (Epidemiology); Humans; Pulmonary Disease Chronic Obstructive; Randomized Controlled Trials as Topic; Research Design; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)Alternative medicineSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionPulmonary DiseasePulmonary Disease Chronic ObstructiveRandomized controlled triallawIntervention (counseling)medicineCOPDHumansPharmacology (medical)Generalizability theoryMedical physicsInternal validityReal life studiesRandomized Controlled Trials as Topicbusiness.industryBiochemistry (medical)Gold standardConfounding Factors EpidemiologicVariance (accounting)Confounding Factors (Epidemiology)AsthmaReal life studieRandomized controlled trials; Real life studies; Asthma; COPDRandomized controlled trialResearch DesignRandomized controlled trialsPhysical therapybusinessStrengths and weaknesses
researchProduct